Goldenwell Biotech, Inc.
GWLL
$0.70
-$0.07-9.09%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -62.40K | 25.00K | 37.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -62.40K | 25.00K | 37.50K |
| Cost of Revenue | -- | -- | 174.80K | -- | -- |
| Gross Profit | -- | -- | -237.20K | 25.00K | -- |
| SG&A Expenses | 34.80K | 31.30K | 9.60K | 30.90K | 28.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.80K | 31.30K | 184.30K | 30.90K | 28.20K |
| Operating Income | -34.80K | -31.30K | -246.80K | -5.90K | -28.20K |
| Income Before Tax | -36.90K | -17.60K | -248.90K | -8.00K | -30.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.90K | -17.60K | -248.90K | -8.00K | -30.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.90K | -17.60K | -248.90K | -8.00K | -30.30K |
| EBIT | -34.80K | -31.30K | -246.80K | -5.90K | -28.20K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 99.00M | 99.00M | 106.70M | 96.43M | 99.00M |
| Average Diluted Shares Outstanding | 99.00M | 99.00M | 106.70M | 96.43M | 99.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |